Literature DB >> 8216224

Interaction of activated protein C with serpins.

J M Hermans1, S R Stone.   

Abstract

The inhibition of activated protein C by six different serine protease inhibitors (serpins) that have arginine residues in the P1 position has been investigated. Micromolar concentrations of C1-inhibitor failed to inhibit the enzyme, and it was inhibited only slowly by antithrombin III with an association rate constant (kass.) of 0.15 M-1.s-1. The kass. values for the other serpins tested (protease nexin I, protein C inhibitor, and mutants of alpha 1-antichymotrypsin and alpha 1-antitrypsin with P1 arginine residues) were at least 1000-fold higher, with P1-Arg-alpha 1-antitrypsin (kass. = 7 x 10(4) M-1.s-1) being the most effective inhibitor. The inhibition with these four serpins appeared to be reversible, with inhibition constants in the nanomolar range. The relatively high value of kass. for protease nexin I (5 x 10(3) M-1.s-1) suggested that it may be involved in the control of activated protein C on the surface of platelets where protein nexin I is present at relatively high concentrations. The value of kass. for protease nexin I, protein C inhibitor and antithrombin III showed a bell-shaped dependence on heparin concentration. At optimal concentrations, heparin accelerated the rate of inhibition by protease nexin I, protein C inhibitor and antithrombin III by 44-, 18- and 13-fold respectively. The kinetic constants for the inhibition of thrombin were also determined, and in all cases the serpins were more effective inhibitors of thrombin. Comparison of the sequences of the active-site regions of activated protein C and thrombin suggested that the more hydrophobic active site of thrombin may be more favourable for interactions with serpins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216224      PMCID: PMC1134845          DOI: 10.1042/bj2950239

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  52 in total

1.  Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor.

Authors:  C Longstaff; P J Gaffney
Journal:  Biochemistry       Date:  1991-01-29       Impact factor: 3.162

2.  Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.

Authors:  P A Patston; N Roodi; J A Schifferli; R Bischoff; M Courtney; M Schapira
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

Review 3.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins.

Authors:  R Huber; R W Carrell
Journal:  Biochemistry       Date:  1989-11-14       Impact factor: 3.162

4.  Enzymatic properties of the one- and two-chain form of tissue plasminogen activator.

Authors:  M Rånby; N Bergsdorf; T Nilsson
Journal:  Thromb Res       Date:  1982-07-15       Impact factor: 3.944

5.  Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity.

Authors:  M M Maimone; D M Tollefsen
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

6.  Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 A resolution and its comparison with other serpins.

Authors:  U Baumann; R Huber; W Bode; D Grosse; M Lesjak; C B Laurell
Journal:  J Mol Biol       Date:  1991-04-05       Impact factor: 5.469

7.  Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.

Authors:  L A Kuhn; J H Griffin; C L Fisher; J S Greengard; B N Bouma; F España; J A Tainer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.

Authors:  M J Heeb; R Bischoff; M Courtney; J H Griffin
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

9.  Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.

Authors:  F España; A Estelles; J H Griffin; J Aznar
Journal:  Thromb Haemost       Date:  1991-01-23       Impact factor: 5.249

10.  Synthesis of glia-derived nexin in yeast.

Authors:  J Sommer; B Meyhack; G Rovelli; R Buergi; D Monard
Journal:  Gene       Date:  1989-12-28       Impact factor: 3.688

View more
  6 in total

1.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

2.  Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.

Authors:  David T Berg; Bruce Gerlitz; Jing Shang; Tommy Smith; Paula Santa; Mark A Richardson; Ken D Kurz; Brian W Grinnell; Ken Mace; Bryan E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

3.  The 2.8 A crystal structure of Gla-domainless activated protein C.

Authors:  T Mather; V Oganessyan; P Hof; R Huber; S Foundling; C Esmon; W Bode
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

4.  Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

Authors:  Rolf Burghaus; Katrin Coboeken; Thomas Gaub; Lars Kuepfer; Anke Sensse; Hans-Ulrich Siegmund; Wolfgang Weiss; Wolfgang Mueck; Joerg Lippert
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

5.  Interaction of protein C inhibitor with the type II transmembrane serine protease enteropeptidase.

Authors:  Thomas A Prohaska; Felix C Wahlmüller; Margareta Furtmüller; Margarethe Geiger
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

Review 6.  Protease Nexin-1 in the Cardiovascular System: Wherefore Art Thou?

Authors:  Celina Madjene; Alexandre Boutigny; Marie-Christine Bouton; Veronique Arocas; Benjamin Richard
Journal:  Front Cardiovasc Med       Date:  2021-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.